Kevin Hughes on the Effects of Lumpectomies for Older Patients

Video

Kevin Hughes, MD, FACS, breast surgeon, Massachusetts General Hospital, discusses the impact of lumpectomies on elderly patients with breast cancer.

Kevin Hughes, MD, FACS, breast surgeon, Massachusetts General Hospital, discusses the impact of lumpectomies on elderly patients with breast cancer.

While patients may feel the effects of anesthetics for up to two weeks and should avoid lifting or stretching much after the surgery, a lumpectomy is actually a minimal-impact procedure, Hughes says. In fact, patients are usually back in their home and going about their usual business in a few days.

Recent Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
Informing Patients With Cancer About the Potential Impact of Immunotherapy on Pregnancy

Informing Patients With Cancer About the Potential Impact of Immunotherapy on Pregnancy

Iryna Singh, NP
July 23rd 2024
Article

An expert explores the complexities of immunotherapy during pregnancy, highlighting risks to the fetus and the crucial role of oncology nurses in patient education and management.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Tailoring Second-Line Treatments for HR-Positive, HER2-Negative Metastatic Breast Cancer

Tailoring Second-Line Treatments for HR-Positive, HER2-Negative Metastatic Breast Cancer

Darlene Dobkowski, MA
July 11th 2024
Article

With several options available for the second-line treatment of HR-positive, HER2-negative mBC, an expert emphasized the importance of tailoring treatment for every patient.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Assisted Reproductive Techniques May Be Safe in BRCA-Mutated Breast Cancer

Assisted Reproductive Techniques May Be Safe in BRCA-Mutated Breast Cancer

Ariana Pelosci
July 5th 2024
Article

Assisted reproductive techniques may be safe for patients with BRCA-mutated breast cancer, according to an ESMO study.

Ribociclib Boosts PFS in HR+/HER2– Advanced Breast Cancer

Ribociclib Boosts PFS in HR+/HER2– Advanced Breast Cancer

Kyle Doherty
July 4th 2024
Article

Compared with combination chemotherapy, ribociclib plus endocrine therapy provided a significant progression-free survival benefit in HR-positive, HER2-negative advanced breast cancer.

© 2024 MJH Life Sciences

All rights reserved.